Release of patients after therapy with unsealed radionuclides

  title={Release of patients after therapy with unsealed radionuclides},
  author={Jack Valentin},
  journal={Annals of the ICRP},
  pages={v - vi}
  • J. Valentin
  • Published 1 June 2004
  • Medicine
  • Annals of the ICRP
Management of patients receiving radionuclide therapy with unsealed radionuclides: a proposed approach to the definition of release criteria in Italy
The aim of the present research is to assess acceptable release criteria (in terms of personal dose-equivalent rate at the moment of hospital discharge) to ensure compliance with the current regulatory framework in Italy.
Beta radiation exposure of staff during and after therapies with 90Y-labelled substances.
Measurements of the dose rate around patients, made using survey meters with sufficient response to beta particles, indicate that the exposure of caregivers and family members is considerably higher than previously assumed, and was dominated by primary beta radiation instead of bremsstrahlung.
Release Criteria and Other Radiation Safety Considerations for Radionuclide Therapy
To optimize clinical efficacy, cost-effectiveness, and accessibility to 131I and other radionuclide therapies and their benefits, such regulations must be based on sound dosimetric and radiobiologic principles and available relevant data.
Radiation protection in radionuclide therapies with 90Y-conjugates: risks and safety
When specific procedures are adopted, a substantial improvement in 90Y manipulation is attainable, reducing doses and increasing safety and for the widespread clinical use of 90Y-conjugates, a completely automatic labelling procedure is desirable.
Unexpected dose to the daughter of a patient treated with iodine-131 for hyperthyroidism.
It is the opinion of the authors that if there are children in the family of a hyperthyroid patient treated with (131)I, they should stay in another house for at least a week, if this is impossible for social reasons, hospitalization of the patient should be considered.
ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals
An overview of therapeutic procedures and a framework for calculating radiation doses for various treatment approaches are provided and specific radiological protection guidance should be provided to patients and carers.
First-day iodine kinetics is useful for individualizing radiation safety precautions for thyroid carcinoma patients
It is possible to individualize radiation safety precautions by taking into account the iodine pharmacokinetics and living conditions of a patient by measuring the activity content within the body for the first 24 h after radioiodine administration.
Release of Patients After Radionuclide Therapy: Radionuclide Releases to the Environment from Hospitals and Patients
Radioiodine treatment for hyperthyroidism and thyroid cancer is the main source of exposure to the public and relatives from patients who have received unsealed radionuclides.
Radiation protection procedures in 131I treatments for thyroid cancer in patients requiring hemodialysis
The data show that hemodialysis can be performed safely during 131I treatments when appropriate radioprotection actions are implemented.